Research programme: histone deacetylase inhibitors - Merck

Drug Profile

Research programme: histone deacetylase inhibitors - Merck

Alternative Names: AP CANC03; AP CANC04; IRBM-1; IRBM-D; MRLB 223

Latest Information Update: 29 Nov 2010

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Istituto di Ricerche di Biologia Molecolare; Merck & Co
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Nov 2010 Preclinical development is ongoing in USA
  • 16 Nov 2010 Pharmacodynamics data from a preclinical trial in Cancer presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
  • 07 May 2007 Preclinical trials in Cancer in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top